Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome
- PMID: 22375882
- PMCID: PMC3407283
- DOI: 10.1111/j.1552-6909.2011.01330.x
Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome
Abstract
Objective: To examine opioid replacement therapy in pregnancy and effect on neonatal outcomes, including length of hospital stay for neonatal abstinence syndrome.
Design: Retrospective descriptive study.
Setting: Labor and delivery unit and neonatal intensive care unit (NICU), Eastern Maine Medical Center, Bangor, Maine.
Participants: One hundred fifty-two opioid-dependent pregnant women on methadone maintenance therapy (MMT) (n = 136) or buprenorphine maintenance therapy (BMT) (n = 16) during pregnancy and their neonates. The neonates were born between January 1, 2005 and December 31, 2007.
Methods: A review of the electronic medical record (EMR) was conducted of all opioid-dependent women who were maintained on MMT or BMT at the time of admission for labor and delivery and their neonates.
Results: Maternal methadone dose and concomitant in-utero exposure to benzodiazepines prolonged the length of hospital stay for neonates. Length of stay was shorter in breastfed neonates than formula-fed neonates or neonates who received formula and breast milk. Neonates with prenatal exposure to MMT spent more days in the hospital (21 vs. 14 days) for treatment of neonatal abstinence syndrome (NAS) than infants with prenatal exposure to BMT.
Conclusion: These findings are consistent with previous research on the simultaneous use of methadone and benzodiazepines during pregnancy and provide further direction for the treatment of opioid dependency during pregnancy. Harm reduction strategies for opioid-dependent pregnant women in substance abuse treatment with MMT may one day include guidance on daily treatment doses and recommendations to avoid the concomitant use of benzodiazepines to lessen NAS. Breastfeeding should be recommended to shorten length of stay. Understanding perinatal and neonatal outcomes of pregnant women on methadone or buprenorphine will help to identify optimal treatment for opioid dependency in pregnancy.
© 2012 AWHONN, the Association of Women's Health, Obsteric and Neonatal Nurses.
References
-
- Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate–addicted gravid women in a methadone treatment program. American Journal of Obstetrics & Gynecology 2009. 2009;201:326.e1–6. - PubMed
-
- Arlettaz R, Kashiwagi M, Das-Kundu S, Fauchere JC, Lang A, Bucher HU. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): Neonatal outcome and social resources. Acta Obstetricia et Gynecologica Scandinavica. 2005;84:145–150. - PubMed
-
- Binder T, Vavrinkova B. Prospective randomized comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birth weight of newborns, early postpartum adaptation and course of neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuroendocrinology Letters. 2008;29(1):80–86. - PubMed
-
- Brown M, Hayes M, LaBrie S. Breast feeding is associated with decreased risk and length of treatment for neonatal abstinence syndrome (NAS) in methadone and buprenorphine exposed infants [Poster]. Presented at Pediatric Academic Societies and Asian Society for Pediatric Research 2011 Joint Meeting; Boston, MA. 2011. Apr-May.
-
- Burns L, Mattick RP, Lim K, Wallace C. Methadone in pregnancy: Treatment retention and neonatal outcomes. Addiction. 2007;102(2):264–270. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
